The estimated Net Worth of Thomas J Bucknum is at least $5.72 Milion dollars as of 17 February 2005. Thomas Bucknum owns over 89,700 units of Biogen Inc stock worth over $5,723,838 and over the last 21 years Thomas sold BIIB stock worth over $0.
Thomas has made over 4 trades of the Biogen Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Thomas exercised 89,700 units of BIIB stock worth $4,082,247 on 17 February 2005.
The largest trade Thomas's ever made was exercising 89,700 units of Biogen Inc stock on 17 February 2005 worth over $4,082,247. On average, Thomas trades about 31,433 units every 48 days since 2003. As of 17 February 2005 Thomas still owns at least 28,750 units of Biogen Inc stock.
You can see the complete history of Thomas Bucknum stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is 14 CAMBRIDGE CENTER, , CAMBRIDGE, MA, 02142.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner oraz Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: